Organizational Restructuring at AstraZeneca China Aims to Strengthen Oncology Business

On July 1st, AstraZeneca China implemented a significant organizational restructuring, dismantling and reorganizing its county-level oncology teams, and integrating them into the Lung Cancer Business Unit and the Urology, Gynecology and Women's Oncology Business Unit. This move is undoubtedly aimed at better focusing on the company's specialized oncology business areas and enhancing its competitiveness in these fields. As a result of this adjustment, there will also be changes in the positions of relevant personnel.

Specifically, Ouyang Haolei, the head of the County-level Oncology Business Department, will be transferred to the Hematology Oncology team, taking on the roles of Executive Director and Head of Hematology Oncology Business. He will report directly to Lai Minlong, AstraZeneca's Global Senior Vice President, General Manager of AstraZeneca China, and General Manager of Oncology Business. Additionally, the current Executive Director of the Hematology Oncology Business Marketing Department, Huang Ying, and the National Sales Director, Wang Huili, will also report to Ouyang Haolei, which is a clear show of trust and support for him in his new position.

At the same time, the Urology and Gynecology Oncology product lines within the Urology, Gynecology and Women's Oncology Business Unit will be integrated, and a Central Region (including Jiangsu, Anhui, Shandong, and Henan) will be established. Dai Xia, the current National Sales Executive Director of the County-level Oncology Business Department, will be transferred to the Urology and Gynecology Oncology Business Department of the Oncology Business Unit, taking on the role of Central Region Sales Executive Director, reporting to Chen Shangyong, the Head of the Urology and Gynecology Oncology Business.

This adjustment is an important strategic move by AstraZeneca in its global business layout. In order to achieve the goal of reaching $80 billion in total revenue by 2023, AstraZeneca plans not only to expand its business scale through "transactions and acquisitions of high-quality assets," but also to fully leverage the advantages of its existing strong areas and focus on high-growth markets globally. This is undoubtedly to ensure the company can achieve sustained and stable performance growth.

According to data from the IMS Report, AstraZeneca is currently ranked second in the oncology business field in China, which means that oncology business is a key focus area for the company. Through this organizational restructuring, AstraZeneca is expected to further improve its market share in the oncology business, laying a solid foundation for the company's long-term development.